Ilan Daskal - 08 Apr 2023 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role
EVP, Chief Financial Officer
Signature
/s/ Ilan Daskal
Issuer symbol
BIO
Transactions as of
08 Apr 2023
Net transactions value
-$113,296
Form type
4
Filing time
11 Apr 2023, 14:39:17 UTC
Previous filing
07 Sep 2022
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIO Bio-Rad A Common Stock Options Exercise $0 +700 +68% $0.000000 1,736 08 Apr 2023 Direct F1, F2
transaction BIO Bio-Rad A Common Stock Tax liability $113,296 -243 -14% $466.24 1,493 08 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIO Restricted Stock Units Options Exercise $0 -700 -50% $0.000000 700 08 Apr 2023 Bio-Rad A Common Stock 700 $0.000000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
F2 Includes 44.9320 and 38.3360 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/30/2022 and 3/31/2023, respectively.
F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F4 On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.